$12.80
0.95% today
Nasdaq, Feb 05, 06:14 pm CET
ISIN
US3968791083
Symbol
GLSI
Sector
Industry

Greenwich LifeSciences Inc Stock price

$12.68
-0.43 3.28% 1M
-0.58 4.37% 6M
+1.45 12.91% YTD
+3.78 42.47% 1Y
-7.04 35.70% 3Y
+6.93 120.52% 5Y
+6.93 120.52% 10Y
Nasdaq, Closing price Tue, Feb 04 2025
-0.30 2.31%
ISIN
US3968791083
Symbol
GLSI
Sector
Industry

Key metrics

Market capitalization $166.67m
Enterprise Value $160.85m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 33.45
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-10.76m
Free Cash Flow (TTM) Free Cash Flow $-7.57m
Cash position $5.82m
EPS (TTM) EPS $-0.81
Short interest 7.83%
Show more

Is Greenwich LifeSciences Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,821 stocks worldwide.

Greenwich LifeSciences Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Greenwich LifeSciences Inc:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Greenwich LifeSciences Inc:

Buy
100%

Financial data from Greenwich LifeSciences Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 1.63 1.63
4% 4%
-
- Research and Development Expense 9.13 9.13
17% 17%
-
-11 -11
15% 15%
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -11 -11
15% 15%
-
Net Profit -11 -11
17% 17%
-

In millions USD.

Don't miss a Thing! We will send you all news about Greenwich LifeSciences Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Greenwich LifeSciences Inc Stock News

Neutral
GlobeNewsWire
7 days ago
STAFFORD, Texas, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided the following update on the expansion of the clinical trial into Europe.
Neutral
GlobeNewsWire
9 days ago
STAFFORD, Texas, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the activation of clinical sites in Poland.
Neutral
GlobeNewsWire
13 days ago
STAFFORD, Texas, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the initiation of new clinical sites in the US.
More Greenwich LifeSciences Inc News

Company Profile

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.

Head office United States
CEO Snehal Patel
Employees 7
Founded 2006
Website www.greenwichlifesciences.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today